Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2015

View Archived Issues

TaiRx starts phase I trial of oral anticancer drug TRX-818

Blood cytokine biomarker signature detects tuberculosis and identifies dormant/active forms

Merck & Co. initiates phase I trial of MK-8591 for HIV-1 infection

Otonomy receives IND application clearance for tinnitus candidate OTO-311

VIS-410 shows activity and reduced duration of symptoms in phase IIa challenge study

Turing Pharmaceuticals files IND for TUR-004

Temsirolimus in recurrent bladder cancer treatment

ContraVir reports preliminary data for tenofovir prodrug in HBV

Proenkephalin plasma levels linked to CKD incidence

Ribociclib and binimetinib in combination for NRAS-mutant melanoma

Insero Health merges into Biscayne Pharmaceuticals

BARDA awards contract to Stratatech for StrataGraft skin substitute

Biosimilar ONS-1045 meets primary and secondary endpoints in phase I trial

SanBio starts phase II trial of stem cell therapy SB-623 in traumatic brain injury

RAD-1901: hybrid SERM/SERD active in breast cancer-derived brain metastasis models

Axovant Sciences begins phase III MINDSET study

Novel DYM mutations related to rare Dyggve-Melchior-Clausen syndrome

Vitamin B12 deficiency linked to diabetic cardiovascular autonomic neuropathy

Merck & Co. reports TrkA inhibitors

Janssen discloses c-Ros-1 inhibitors

Beijing Hanmi patents ROR-gamma modulators

Synta Pharmaceuticals HSP90-targeted SDC-TRAPs

Chungnam National University introduces cardiac myosin activators

Tarix Orphan receives FDA fast track designation for TXA-127 in DMD

Akebia reaches agreement with FDA and EMA on phase III program for vadadustat

Genzyme completes acquisition of vandetanib from AstraZeneca

FDA places clinical hold on axalimogene filolisbac

Guadecitabine receives FDA orphan drug designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...